Completed PHASE1 INTERVENTIONAL 5-arm NCT02077452

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes

A Randomized, Double-blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of HMS5552 in Adult Patients With Type 2 Diabetes Mellitus

Sponsor: Hua Medicine Limited

Conditions Type 2 Diabetes Mellitus

Interventions HMS5552 Placebo

Updated 5 times since 2017 Last updated: Nov 17, 2017 Started: Mar 31, 2014 Primary completion: Sep 30, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Type 2 Diabetes Mellitus and is currently completed. Hua Medicine Limited leads this study, which shows 5 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hua Medicine Limited

Data source: Hua Medicine Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.